28 results about "Oligodendrocyte progenitor" patented technology

Methods for differentiating pluripotent stem cells to neuroectoderm in dynamic suspension culture using small molecule or protein inhibitors of TGFβ / Activin / Nodal signaling and BMP signaling are provided. Also provided are methoc and protocols for differentiating pluripotent stem cells such as human embryonic stem cells first to neuroectoderm, then further to glial progenitor cells, and further to oligodendrocyte progenitor cells (OPCs), and compositions obtained thereby. The methods of the present disclosure reproducibly produce neuroectoderm progenitor cells by day 7 of the differentiation process, glial progenitor cells by day 21 of the differentiation process and OPCs by day 42 of the differentiation process.

Methods for generating human vascular leptomeningeal cells (VLMCs) from human oligodendrocyte progenitor cells (OPCs) are provided using chemically-defined culture media that allow for generation of differentiated cells in a 34-day culture protocol. Methods of generating human VLMCs from human pluripotent stem cells using chemically-defined culture media in a 40 day culture protocol are also provided. Culture media, isolated cell populations, and kits are also provided.

Methods for differentiating pluripotent stem cells to neuroectoderm in dynamic suspension culture using small molecule or protein inhibitors of TGFβ / Activin / Nodal signaling and BMP signaling are provided. Also provided are methot and protocols for differentiating pluripotent stem cells such as human embryonic stem cells first to neuroectoderm, then further to glial progenitor cells, and further to oligodendrocyte progenitor cells (OPCs), and compositions obtained thereby. The methods of the present disclosure reproducibly produce neuroectoderm progenitor cells by day 7 of the differentiation process, glial progenitor cells by day 21 of the differentiation process and OPCs by day 42 of the differentiation process.

Provided is a medicine for promoting induction of differentiation of oligodendrocyte progenitor cells into oligodendrocytes, and a medicine for promoting remyelination. The medicine contains a vitamin D derivative represented by formula (1) or a pharmaceutically acceptable salt or solvate thereof and used in combination with an immunosuppressant.

A method of generating oligodendroglial progenitor cells and pre-myelinating oligodendrocytes is disclosed. Uses of the cell populations are further described.

Compositions comprising a population of oligodendrocyte progenitor cells (OPCs), as well as methods of making and using the same, are provided. In one aspect, a container comprising a composition, where the composition comprises a population of cells comprising a plurality of OPCs, and where the population of cells comprises less than 15% undesirable cell types is provided. In another aspect, the population of cells comprises less than 15% undesirable epithelial lineage cells. In yet another aspect, the population of cells comprises less than 2% K7 positive cells. In an aspect, a population of cells comprising a plurality of oligodendrocyte progenitor cells is capable of forming less than one epithelial cyst per 100,000 cells in a cyst assay is provided. An even further aspect of the present disclosure is a container comprising a composition, where the composition comprising a plurality of oligodendrocyte progenitor cells is useful in treating treat stroke, spinal cord injury, and multiple sclerosis.

The present invention provides a method for promoting the differentiation of mesenchymal stem cells (MSCs) into oligodendrocyte progenitor cells, which includes primary culturing the isolated MSCs, followed by secondary passage culturing, then treating them with a gene expression vector containing the "key gene for oligodendrocyte progenitor cell differentiation", and further performing differentiation culture using the "oligodendrocyte progenitor cell differentiation medium". Through specific cell differentiation treatment and culture processes, the present invention uses a cell culture matrix treated with recombinant human laminin to culture MSCs and promote their differentiation, so as to obtain oligodendrocyte progenitor cells derived from MSCs in a relatively short time. The present invention further provides a method for efficiently harvesting oligodendrocyte progenitor cells. Specifically, through a rate-limiting shaking method, oligodendrocyte progenitor cells are harvested and allowed to further proliferate, and a relatively large amount of oligodendrocyte progenitor cells with high purity can be harvested in a short time for the production of cell therapy products.

Methods are provided for differentiating human pluripotent stem cells into dorsal neuroectodermal progenitor cells and further into glial progenitor cells and oligodendrocyte progenitor cells (OPCs) using inhibitors of BMP signaling and MAPK / ERK signaling. Also provided are cells and cell compositions obtained by such methods, and uses of such cells. Further provided are methods and protocols for effectively differentiating human pluripotent stem cells into OPCs in the absence of the ventral morphogen SHH or an activator of SHH signaling. The methods of the present disclosure reproducibly generate dorsal neuroectodermal progenitor cells at day 7 of the differentiation process, glial progenitor cells at day 21 of the differentiation process, and OPCs at day 42 of the differentiation process.

The present application provides O-GlcNAc glycosidase (O-GlcNAcase, OGA) inhibitors and their applications for promoting remyelination. Specifically, by comparing the promoting effects of different types of OGA inhibitors on OPC differentiation and remyelination in the models of OPC differentiation and remyelination, the OGA inhibitors with drugability of the present application are obtained. The OGA inhibitors of the present application have wide application value in preventing and / or treating demyelination and its related diseases.

The invention provides an oligodendrocyte precursor cell line, a method, a kit and application. Specifically, the cell line comprises a first gene sequence and a second gene sequence; the first gene sequence and the second gene sequence are separated from each other; wherein the first gene sequence comprises a Sirt2 gene and a first subsequence; the second gene sequence comprises a nuclear localization signal gene and a second subsequence; wherein peptide chains independently expressed by the first subsequence and the second subsequence are free of fluorescence and can be spontaneously combined to form fluorescent protein when meeting. The cell line can be used for high-throughput screening of drugs or molecules for promoting differentiation of oligodendrocyte precursor cells, and has the advantages of low cost and high efficiency.

Provided is a differentiation agent consisting essentially of SOX9 for generating oligodendrocyte progenitor cells (OPCs) from pluripotent stem cells (PSCs). Also provided are methods of generating PSCs and methods of using PSCs to generate OPCs and oligodendrocytes.SOLUTION: A method comprising culturing pluripotent stem cells (PSCs) to produce a population of cells comprising oligodendrocyte progenitor cells (OPCs), wherein the PSCs express engineered nucleic acids encoding SOX9 at a level sufficient to differentiate the PSCs into OPCs in the absence of other transcription factors encoded by the engineered nucleic acids.SELECTED DRAWING: Figure 2C

The present disclosure relates to a preparation of CD140a / PDGFRα positive cells that comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a / PDGFRα. The preparation of cells is derived from pluripotent cells that were derived from skin cells, fibroblasts, umbilical cord blood, peripheral blood, bone marrow, or other somatic cells. The cell preparation has an in vivo myelination efficiency that is equal to or greater than the in vivo myelination efficiency of a preparation of A2B5+ / PSA-NCAM-sorted fetal human tissue derived oligodendrocyte progenitor cells. Methods of making, isolating and using the disclosed cell preparation are also described.

A method of generating oligodendroglial progenitor cells and pre-myelinating oligodendrocytes is disclosed. Uses of the cell populations are further described.

An O-GlcNAcase (OGA) inhibitor for promoting remyelination and use thereof. Specifically, the OGA inhibitor with druggability is obtained by comparing the promoting effects of different types of OGA inhibitors on oligodendrocyte precursor / progenitor cell differentiation and remyelination in an OPC differentiation model and a remyelination model. The OGA inhibitor has wide application value in preventing and / or treating demyelination and related diseases thereof.

Methods for generating pre-oligodendrocyte progenitor cells (pre-OPCs) and oligodendrocyte progenitor cells (OPCs) from human pluripotent stem cells are provided using chemically-defined culture media that allow for generation of pre-OPCs and OPCs in as little as three days. Culture media, isolated cell populations and kits are also provided.

Methods for generating pre-oligodendrocyte progenitor cells (pre-OPCs) and oligodendrocyte progenitor cells (OPCs) from human pluripotent stem cells are provided using chemically-defined culture media that allow for generation of pre-OPCs and OPCs in as little as three days. Culture media, isolated cell populations and kits are also provided.

Provided herein is a differentiation agent that consists essentially of SOX9 for the production of oligodendrocyte progenitor cells (OPCs) from pluripotent stem cells (PSC). Also provided herein are methods of producing the PSCs and methods of using the PSCs to produce OPCs and oligodendrocytes.

The present disclosure relates to methods and compositions using RAP, a derivative of RAP, a variant of RAP, or a fragment of RAP to inhibit LRP1, a myelin debris receptor. The methods and compositions involve increasing, promoting, restoring, and / or enhancing differentiation of oligodendrocyte progenitor cells, myelin protein expression, mature oligodendrocyte marker expression, and / or myelination. The methods and compositions disclosed herein inhibit or block pathological activation of RhoA in OPCs. The methods and compositions also involve alleviating one or more symptoms of MS and treating MS, including slowing or stopping MS progression.

The present disclosure is directed to methods of producing oligodendrocyte progenitor cells (OPCs). In addition, methods of treating demyelinating diseases using oligodendrocyte progenitor cells (OPCs) are also disclosed.

Provided herein is a differentiation agent that consists essentially of SOX9 for the production of oligodendrocyte progenitor cells (OPCs) from pluripotent stem cells (PSCs). Also provided herein are methods of producing the PSCs and methods of using the PSCs to produce OPCs and oligodendrocytes.

Methods for generating pre-oligodendrocyte precursor cells (pre-OPCs) and oligodendrocyte progenitor cells (OPCs) from human pluripotent stem cells are provided using chemically defined culture media that allow for the generation of pre-OPCs and OPCs in as few as three days. Culture media, isolated cell populations, and kits are also provided.

To provide induction of neural progenitor cells, oligodendrocyte progenitor cells, and oligodendrocytes by stem cell differentiation using landmark transcription factors.SOLUTION: Novel methods of inducing human iPSC-derived neural progenitors, oligodendrocyte progenitors, oligodendrocytes with unprecedented efficiency and functionality. The core of the present invention is the use of experimentally discovered transcription factors in a previously unknown manner at key differentiation decision points along the pathway from pluripotency to ectoderm to neuroectoderm to NPCs to OPCs to oligodendrocytes.SELECTED DRAWING: None

The present disclosure provides methods for reprogramming a cell into a glial cell (e.g., an oligodendrocyte progenitor cell), wherein the method comprises passing a cell suspension comprising the cell and a glial cell reprogramming factor through a constriction, wherein the constriction deforms the cell, thereby causing a perturbation of the cell such that the glial cell reprogramming factor enters the cell.

Provided are methods for treating Alzheimer's Disease and / or ameliorating at least one symptom thereof. In some embodiments, the methods include administering to a. subject with AD an inhibitor of a clusterin biological activity, wherein the composition is administered via a route and in an amount sufficient to inhibit the clusterin biological activity to thereby treat the subject's. AD and / or ameliorate at least one symptom thereof. Also provided are methods for reducing and / or inhibiting myelin decay in a subject in need thereof and methods for inhibiting differentiation of oligodendrocyte progenitor cells (OPCs) to mature oligodendrocytes, the method comprising contacting the OPCs with a clusterin gene product or a functional fragment or derivative thereof.

The invention provides an O-GlcNAc glucoside hydrolase (O-GlcNAcase, OGA) inhibitor for promoting remyelination and application of the O-GlcNAc glucoside hydrolase (O-GlcNAcase, OGA) inhibitor. Specifically, the OGA inhibitor with druggability is obtained by comparing the promotion effects of different types of OGA inhibitors on OPC differentiation and myelin regeneration in an oligodendrocyte progenitor cell differentiation model and a myelin regeneration model. The OGA inhibitor provided by the invention has wide application value in prevention and / or treatment of demyelination and related diseases thereof.

Provided are crystals of a vitamin D derivative represented by formula (1) or crystals of a solvate of a vitamin D derivative represented by formula (1). Such crystals are useful as a pharmaceutical for promoting induction of differentiation of oligodendrocyte progenitor cells into oligodendrocytes.

Methods for generating human vascular leptomeningeal cells (VLMCs) from human oligodendrocyte progenitor cells (OPCs) are provided using chemically-defined culture media that allow for generation of differentiated cells in a 34-day culture protocol. Methods of generating human VLMCs from human pluripotent stem cells using chemically-defined culture media in a 40 day culture protocol are also provided. Culture media, isolated cell populations, and kits are also provided.

The present disclosure is directed to methods of producing oligodendrocyte progenitor cells (OPCs). In addition, methods of treating demyelinating diseases using oligodendrocyte progenitor cells (OPCs) are also disclosed.